GEN Exclusives

More »

GEN News Highlights

More »
Feb 26, 2007

Avalon Pharmaceuticals Initiates Primary Screening Phase in Novartis Collaboration

  • Avalon Pharmaceuticals initiated the primary screening phase under its drug discovery collaboration with Novartis. The collaboration aims to discover small molecule therapeutic compounds targeted against a pathway selected by Novartis. The terms of the collaboration provide for upfront, research-support, and milestone payments.

    Avalon is using its AvalonRx® drug discovery platform to screen, identify, and characterize compounds from the Novartis  proprietary compound library. Following Avalon's successful identification of a screen signature by monitoring large-scale gene expression changes resulting from disrupting the selected pathway, the parties have agreed to initiate the primary screen against a large subset of Novartis' compound library. Under the terms of the agreement, the initiation of the screening phase triggers a $500,000 payment to Avalon for research support.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?